

**This Page Is Inserted by IFW Operations
and is not a part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- **BLACK BORDERS**
- **TEXT CUT OFF AT TOP, BOTTOM OR SIDES**
- **FADED TEXT**
- **ILLEGIBLE TEXT**
- **SKEWED/SLANTED IMAGES**
- **COLORED PHOTOS**
- **BLACK OR VERY BLACK AND WHITE DARK PHOTOS**
- **GRAY SCALE DOCUMENTS**

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
5 June 2003 (05.06.2003)

PCT

(10) International Publication Number
WO 03/045414 A2

(51) International Patent Classification⁷: **A61K 35/80**,
31/716, A61P 31/04, 31/10, 31/12, 37/04, 35/00

(21) International Application Number: PCT/EP02/13512

(22) International Filing Date:
29 November 2002 (29.11.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
09/999,202 30 November 2001 (30.11.2001) US

(71) Applicant (*for all designated States except US*): **LAB-ORATOIRES GOËMAR S.A.** [FR/FR]; ZAC de la Madeleine, F-35400 Saint Malo (FR).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **YVIN, Jean-Claude** [FR/FR]; 2, rue Gabriel Désgrés, F-35400 Saint Malo (FR).
VETVICKA, Vaclav [CZ/US]; 3620 Brookhollow Drive, Louisville, KY 40220 (US).

(74) Agents: **KOCH, Gustave et al.**; Cabinet Plasseraud, 84, rue d'Amsterdam, F-75440 Paris Cedex 9 (FR).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 03/045414 A2

(54) Title: THERAPEUTICAL TREATMENTS

(57) Abstract: Therapeutical method comprising administration to a patient of an effective amount of especially soluble laminarin for the treatment of tumors and more generally of cancers of the group comprising breast cancer, lung cancer, oesophagus cancer, stomach cancer, intestine and colon cancers, and for the treatment of viral, bacterial and fungal diseases as well as diseases related to immunostimulant deficiencies of human beings and warm-blood animals.

Therapeutical treatments

The invention relates to therapeutical treatments.

5 More particularly it relates to therapeutical treatments based on the immunostimulant, antitumoral and cytokine synthesis-inducing and -accelerating activities of laminarin, especially of soluble laminarin, a well known marine glucan, which activities were surprisingly and unexpectedly discovered by the Applicants in the course of extensive and thorough studies
10 and searches and on which are founded the hereafter disclosed and claimed applications and uses.

 The therapeutical treatments in question are intended to treat cancers, viral, bacterial and fungal diseases as well as diseases related to immunostimulant deficiencies of patients, i.e. of human beings and warm-
15 blood animals.

 The Applicant's discovery is all the more important and unexpected
 - as comparative tests, which are hereafter disclosed, show the superiority from the point of view of efficiency of especially the soluble form of laminarin with respect to another glucan, i.e. lentinan, which is extracted
20 from a mushroom and which is used in Japan since 25 years as an adjunctive in antitumor therapy, and

 - as glucans of the laminaran and pachyman type (single helical form) were considered as "antitumor negative" i.e. as not having antitumor properties in comparison with glucans of the family comprising lentinan, curdlan, schizophyllan and pachymaran (triple helical form) which were
25 considered as "antitumor positive" i.e. as acting against tumors. (see G. CHIHARA, National Cancer Center Research Institute, Tokyo, Japon, article under the title "Immunopharmacology of lentinan and glucans", published in EOS-Riv.Immunol.Immunopharmacol., 5:85, 1983).

Another important aspect of the invention comes from the fact that it makes available therapeutical treatments which permit to fight again the increasing occurrence of antibiotic-resistant, nosocomial infections which are often untreatable by classical procedure, the treatments of these diseases by immunomodulators such as cytokines, while efficient, being associated with the inherent toxicity of these materials.

Laminarin is extracted from brown algae reason for which it is called marine glucan and its molecular weight is from about 2500 to about 6000.

Laminarin is consisting of a main linear chain of 15 to 35 glucopyranose units joined by acetalic β -(1,3) linkages and to which a low proportion of branches, in essentially primary position of principally β -D-glucopyranose units are joined by β -(1,6) linkages, some of these β -D-glucopyranose units being joined to the main chain.

The average degree of polymerisation is close to 25.

The terminal unit of the main chain is consisting of glucose or of mannitol, thus providing two types of molecules respectively called G or M.

Complete hydrolysis provides glucose and manitol.

Two forms of laminarin have been identified; one of these forms is the here preferably used soluble form, while the other one is insoluble in water, the latter being probably caractéized by few or even no branches.

Both the soluble and the insoluble form may be obtained by extraction from e.g. laminaria species; two of these species are laminaria digitata and laminaria hyperborea.

Soluble laminarin occurs under the form of a white to beige powder which is odourless and tasteless ; the soluble form is very hygroscopical and water-soluble (up to 60g/l), while being substantially insoluble in ethanol, 2-propanol and acetone.

The identification of soluble laminarin may be carried out by way of liquid chromatography using, for example, a device comprising an amperometric detector.

Procedure may be as follows, using

- an anion-exchange column, fitted with a non-porous, polymeric resin whose particle size is about 5 μ m, the length of the column being 250mm and the internal diameter 4mm,
- 5 - a pulsed amperometric detector equipped with a gold electrode,
- a mobile phase consisting of the mixture of a solution A with a solution B, the solution A initially representing 30% and the solution B 70%, the latter becoming isocratic of A after 4 minutes, which means that the mobile phase is only consisting of A.

10 Solution A is obtained by dissolving 41g of sodium acetate in 950 ml of water, free of particles, and by introducing 8,2ml of NaOH of 46-48%.

Solution B is a 150 mM solution of NaOH obtained by mixing 8,2ml of NaOH of 47% with 990ml of water, free of particles.

15 A quantity of 50ml of the solution to be examined is injected and eluted at a rate of 1ml/min during 15 minutes.

The thus obtained chromatogramm comprises a Gauss pic of retention comprised between 5,8 and 12 minutes, of maximum amplitude located at about 8 minutes.

20 The pH of a solution of 1g of soluble laminarin in water, free of carbon dioxide, completed to 10ml, is from 6,5 to 7,5.

The combustion residue of 1g of soluble laminarin is not higher than 5%.

25 The fucan content of soluble laminarin obtained by liquid chromatography dosing of the fucose content of the product obtained by total hydrolysis of the said soluble laminarin appears to be lower than 5%.

As mentioned hereabove, laminarin is extracted from brown macrophytic marine algae of the Pheophyceae type, in particular from fucales or laminariales.

Various extraction methods can be used.

Reference may be made for example to the method described by Black et al., Appl. Chem. 1951, 1, pages 505 to 517.

More generally, laminarin can be obtained from brown algae by any extraction process provided it enables the constituents other than laminarin
5 (wall polysaccharides, salts. etc.) to be successively removed.

In particular, these processes use steps involving grinding, precipitation in an acid or basic medium, ultrafiltration and dialysis.

The thus obtained product is consisting of a mixture of the soluble and the insoluble forms of laminarin, the respective proportions of which vary
10 according to the selected algae.

For example, laminaria digitata or laminaria saccharina provide a mixture comprising about 90% by weight of the soluble form, while laminaria hyperborea provides a mixture comprising about 80% by weight of the insoluble form.

15 The latter is separated by precipitation.

The following non-limiting example illustrates the extraction process of soluble laminarin.

EXAMPLE 1

20 **Process for the Extraction of soluble laminarin from Laminaria Saccharina**

300 g of fresh algae of the Laminaria saccharina type. harvested in August, are subjected to cryobursting (-40° C.) by the process described in
25 French patent no. 74 35162.

The product thus obtained has a mean particle diameter of between 50 and 100 µm and a solids content of 10-12%. A quantity of 0.9 l of 0,3% sulfuric acid is added gradually to 300 g of this product. Extraction is performed in a water bath at a temperature of about 80° C, for 1 hour, with
30 stirring.

This operation is repeated twice.

After neutralization, the extract obtained is treated with polyvinylpyrrolidone in a dose of about 1% by weight. This is done by introducing 9 g of polyvinylpyrrolidone (PVP) into a volume of 90 ml of
5 extract. The PVP is left to thicken for about 2 hours. The resulting solution is added to about 0.9 liter of extract, the mixture being stirred for 30 min and then filtered under vacuum on a Whatman GF/A filter.

The thus obtained liquid is subjected to tangential ultrafiltration on a carbon-ceramic tubular membrane of the "Carbosep" type with a porosity of
10 50.000 Daltons. A pressure of 1 bar is maintained on the filtration column during the operation.

This gives a filtrate having a volume of about 0.8 liter and a pH of 5.5. The filtrate is maintained about one night at about 4°C; the precipitated insoluble form of laminarin is removed by filtration and the thus treated
15 filtrate is then dialyzed on a cellulose ester membrane of the SPECIRA Pore type with a porosity of 500 or 1000 Daltons. The dialyzate is then lyophilized to give 7 g of dry powder, corresponding to pure soluble laminarin.

o o o o

In the course of the above mentioned studies and searches carried out
20 especially on soluble laminarin, the Applicants performed more particularly experimentations to determine its ability to act on the defence reactions responsible for cytotoxicity.

In that respect, Applicants first carried out an in vitro cytotoxicity assay on spleen cells isolated from spleen of Balb/c mice by standard methods.

25 These tests were conducted to evaluate the effects of soluble laminarin on the cytotoxicity of NK (Natural Killer) cells of mouse and to compare these effects with those of two known glucans, ie.

1. a yeast-derived glucan called BEI and purchased from the firm Biopolymer Engineering, Inc., St. Paul, MN, USA and

2. the above-mentioned lentinan which is purchased from the firm Sigma St. Louis, MO, USA), lentinan being a 1,3- β -D-glucan which can be isolated from the edible mushroom called *Lentinus edodes*.

The spleens isolated from the above said Balb/c mice were placed into Petri dishes containing RPMI 1640 medium obtained from Life Technologies USA, supplemented with 5% by weight of FCS (fetal calf serum from Life Technologies USA). The spleens were cut into small pieces and a suspension was made by pressing the minced spleens against the bottom of Petri dishes containing PBS (Phosphate Buffered Saline obtained from Biowhittaker Inc, 8830 Biggsford Road, Walkersville, MD 21793 USA). The thus obtained pieces of tissue were gently teased over stainless steel screens using a plunger of a 5-ml syringe. Large debris and cell clumps were removed by layering the cell suspension over 3 ml of heat-inactivated FCS for 10 minutes on ice. After elimination of erythrocytes by incubation during 10 seconds in distilled water and five washes in cold PBS, the thus obtained cells which are called splenocytes, were resuspended in PBS and counted.

Procedure was as follows

An amount of 0,25 ml of trypan blue (obtained from Sigma) solution (0,4 % w/v in water) was mixed with 0,15 ml PBS and 0,1 ml of the above cell suspension (which comprises 2.6×10^6 cells / ml).

The resulting mixed solution was allowed to stand for 5 mn at room temperature.

Then a small amount of the suspension was transferred either to an hemocytometer chamber or on a cover glass and the cells counted under a microscope.

Non viable cells could be easily identified as they were stained in blue.

The viability of the cells, represented by V%, is determined using the formula :

$$V \% = \frac{\text{Number of viable cells}}{\text{Number of viable cells} + \text{number of non viable cells}} \times 100$$

Only cell suspensions for which V% was found to be higher than 95% were used in the subsequent experiments.

5 The evaluation of the cytotoxicity of these cell suspensions was conducted by using a non radioactive cytotoxicity assay marketed under the trademark CYTOTOX 96 by Promega, Madison, WI, USA.

For these experiments, the splenocytes which are also called “effector cells” were pre-treated during 30 minutes by mixing the suspensions containing
10 them respectively with soluble laminarin, with lentinan and with BEI glucan ; the mixtures were subsequently incubated with suspensions of target cells of tumor cell line YAC-1 which is known to be relatively resistant to normal inactivated N K cells.

The specificity of the assay was established by using the following
15 three different ratios effector cells/target cells denoted ET : 10:1, 50:1 and 100:1.

For each ratio, 3 counts were carried out and experiments were repeated 3 times on 3 different days.

Controls consisted of effector cells incubated only with PBS.

20 More particularly, the above cell suspensions of splenocytes (effector cells) were diluted to 10^6 cells /ml and placed in individual wells of V-shaped 96-well microplates at a concentration of 0.1 ml/well.

Laminarin, lentinan and BEI glucan which occur in the form of powders, were added after dissolution in PBS at an identical concentration of
25 2 μ g/ml in PBS and the plates were incubated for 30 minutes at 37°C in an humidified CO₂ incubator.

After incubation, the plates i.e. the incubated cells contained in the wells were washed three times with RPMI 1640 medium, and 50 μ l of the suspension of target cell line YAC-1 were added in each well, respecting the
30 above “effector cells/target cells” ratios or E T : 10:1, 50:1 and 100:1.

For each of these ratios, 3 individual wells were used, the number of target cells being respectively 10^4 , 2×10^3 , and 1×10^3 .

In addition, target cells for spontaneous release control, target cells for maximum release control and effector cells release control were introduced into appropriate wells, i.e. 3 individual wells for each concentration used.

The expressions spontaneous release control, maximum release control and effector cells release control respectively mean

- Target cells spontaneous LDH release
- LDH release from wells with target cells only after addition of lysis solution
- Effector cells (NK cells) spontaneous LDH release.

Basically, it is necessary to obtain the values of spontaneous release from both target and effector cells, and these values serve as a background. The maximum release control serves as 100%.

After spinning the plates at 250g for 5 minutes in a centrifuge, the plates were incubated for 4 hours at 35°C in a humidified CO₂ incubator.

For evaluating the cytotoxic activity of the effector or N K cells, procedure was as follows, using the instructions of the manufacturer PROMEGA.

Here again, use was made of the non radioactive Cytotoxicity Assay KIT marketed under the Trademark CYTOTOX 96 by PROMEGA.

A quantity of 10 µl of lysis solution, included in the Kit, was added 45 min before the end of incubation into appropriate control wells, i.e. into wells with maximum release control.

Next step was spinning the plates at 250xg for 5 min in the centrifuge, followed by transfer of 50µl of supernatant into the wells of flat-bottom 96-well microplates.

A quantity of 50µl of reconstituted substrate (12ml of assay buffer added to a bottle of substrate mix and used as reconstituted substrate) was

added into each well ; then the plates were covered and incubated for 30 minutes at room temperature at dark.

The optical density of each well was then determined at 492nm using a reader consisting of a kit marketed by Tecan U.S., Research Triangle Park, NC under the trademark STL ELISA.

The specific cell-mediated cytotoxicity was calculated using the following formula disclosed in the manufacturer's instruction comprised in the kit :

10

$$\% \text{ cytotoxicity} = \frac{100 (\text{OD}_{492} \text{ experimental} - \text{OD}_{492} \text{ spontaneous})}{\text{OD}_{492} \text{ maximum} - \text{OD}_{492} \text{ spontaneous}}$$

wherein

- "OD₄₉₂ experimental" is the optical density measured at 492 nm of target cells lysed in presence of effector cells
- 15 - "OD₄₉₂ spontaneous" is the spontaneous release i.e. the optical density measured at 492nm of the suspension of target cells incubated with medium alone and
- "OD₄₉₂ maximum" is the maximum release i.e. the optical density measured at 492 nm of target cells lysed with the solution provided
- 20 in the kit.

For each of laminarin, BEI, Lentinan and the control, three experiments were carried out at each of the above identified three "effector cells/target cells" ratios.

From the average value of the three experiments in each case the average percentage of killed cells was determined.

25

The thus determined percentages are collected in the following Table I.

TABLE I

Effector cells/target cells ratio (ET)	% of Killed cells (recorded value and standard deviation)		
	ET = 10:1	ET =50:1	ET =100:1
Lentinan	40.1+4.6	46.3+2.3	52.8+2.4
BEI	36.2+4.9	46.8+2.4	56.3+2.6
Laminarin	48.1+4.4	57.3+5.3	72.7+5.5
Control	19.6+7.1	29.2+3.9	40.4+4.8

5 On the graphical representation of the herewith attached Fig.1, the percentage of killed cells collected in table I is plotted on the Y axis ; on the X axis are represented the above said three ratios in connection with each product tested, i.e. soluble laminarin, BEI, Lentinan and the control.

10 The hereafter commented conclusions can be drawn from examination of Figure 1.

As a function of the increase of the value of ET, the controls (effector cells incubated with PBS only) showed a steady increase in killing of target cells.

15 The comparison of the killing induced by the soluble laminarin with the killing induced by the control, i.e. the unstimulated NK cells, shows significant differences at P 0.05 level (which means that each figure is provided with $\pm 5\%$); thus, at ET 10:1, the soluble laminarin stimulated NK cells were 245 % more cytotoxic, at ET 50:1 they were 196% more cytotoxic and at ET 100:1 they were 180 % more cytotoxic than the control.

20 Similarly, when soluble laminarin stimulated NK cell killing was compared to Lentinan-stimulated NK cell killing, soluble laminarin was again found to be significantly more active at P 0.05 level: at ET 10:1 it was 133%,

at ET 50:1 it was 123% and at ET 100:1 it was 130% more active than lentinan.

The comparison with BEI-stimulated cell killing shows that soluble laminarin was again significantly more active at P 0,05 level : at ET 10:1 it was
5 132 %, at ET 50:1 it was 122% , and at ET 100:1 it was 129% more active than BEI.

Consequently, Laminarin clearly appears as being the most active of the three tested glucans.

These results thus clearly demonstrate that soluble laminarin has very
10 strong stimulative effects on natural killer cells, which respond to the stimulation by enhanced killing of tumor cells.

The above said data have been confirmed by additional experiments where the effects of soluble laminarin on tumor growth *in vivo* were evaluated ; yeast derived glucan BEI was used for comparison.

15 In these additional experiments, mice were inoculated with mouse breast cancer cell line 64Ptas. Experimental treatment was achieved by daily intraperitoneal injection during 14 days of two different doses of soluble laminarin and BEI diluted in PBS; the said two different doses were respectively 100 and 250µg of laminarin per injection.

20 At the end of the 14 days treatment, the mice were killed, tumors were removed and weighted.

In the case of the soluble laminarin treated mice, the weight of the tumors represented 28% with respect to the weight of the tumors treated with the control and in the case of BEI it represented 41% with respect to to the
25 weight of the tumors treated with the control.

These results clearly demonstrate significant inhibition of cancer growth in laminarin treated mice as well as its superiority with respect to the effect obtained with BEI.

By way of consequence an object of the invention is consisting in a
30 therapeutical method comprising administration of an amount of laminarin,

preferably soluble laminarin, comprised within a composition comprising said laminarin and a pharmaceutically acceptable carrier, to a human or to a warm-blood animal suffering from a tumor or from a cancer or from a viral disease, a bacterial disease, a fungal disease, a disease of the immune system, an auto-
5 immune disease or a disease related to a deficiency of immunostimulation in the human or animal, wherein the amount of laminarin is effective to treat the tumor or cancer or the disease.

An object of the invention is also consisting in a therapeutical method comprising administration to a patient of an effective amount of especially
10 soluble laminarin for the treatment of tumors and more generally of cancers of the group comprising breast cancer, lung cancer, oesophagus cancer, stomach cancer, intestine and colon cancers, and for the treatment of viral, bacterial and fungal diseases as well as diseases related to immunostimulant deficiencies of human beings and warm-blood animals.

15 The expression "effective amount" designates throughout the specification the concentration or quantity or level of laminarin that can attain the contemplated medical end such as control or destruction of cancer cells or virally infected cells without producing unacceptable toxic symptoms; the said effective amount will vary with factors such as the particular condition being
20 treated, the physical condition of the patient and the duration of the treatment.

Another object of the invention is consisting in a therapeutical method of treating, by stimulation of the NK cells of a patient, of tumors and more generally of cancers of the group comprising breast cancer, lung cancer, oesophagus cancer, stomach cancer, intestine and colon cancers, and of viral,
25 bacterial and fungal diseases as well as diseases related to immunostimulant deficiencies of human beings and warm-blood animals, said method comprising administration to a patient of an effective amount of especially soluble laminarin.

Another object of the invention is consisting in a therapeutical method
30 of treating, by stimulation of the NK cells of a patient, of tumors and more

generally of cancers of the group comprising breast cancer, lung cancer, oesophagus cancer, stomach cancer, intestine and colon cancers , and of viral, bacterial and fungal diseases as well as diseases related to immunostimulant deficiencies of human beings and warm-blood animals, said method
5 comprising administration to the patient of an amount of laminarin, preferably soluble laminarin comprised within a composition comprising said laminarin and a pharmaceutically acceptable carrier, wherein the amount of laminarin is effective to treat the tumors, the cancers and the diseases.

Applicants also have investigated the effect of laminarin on the
10 production of TNF-alpha, i.e. tumor necrosis factor alpha which is a pleiotropic cytokine secreted primarily by monocyte/macrophages and T lymphocytes, respectively.

TNF-alpha was originally described as a factor present in the serum of *Bacillus Calmette-Guerin*- treated mice that induced tumor necrosis in tumor
15 bearing mice.

TNF-alpha is the principal mediator of natural immunity against Gram-negative bacteria and a key mediator of inflammatory response and septic shock.

In addition, it has many other activities, including a cytotoxic effect
20 toward certain target cells and tumors, induction of MHC "major histocompatibility complex" class I and II molecules on target cells, activation of polymorphonuclear leukocytes, and co-stimulatory effects on T and B lymphocytes.

Extracellular forms of TNF receptors are shed and appear in biological
25 fluids, potentially acting as regulators of TNF activity ; TNF activity means any biological activity, TNF can have on biological systems.

Older bioassays for TNF-alpha were based on its cytotoxic effects toward target cells. Recently, highly specific commercial kits made the evaluation of TNF-alpha production easier and more reliable.

By way of consequence it is thus of interest to stimulate the production of TNF-alpha and Applicants surprisingly and unexpectedly found that such a stimulation becomes possible when treating with laminarin especially soluble laminarin, an organism whose natural defences against especially cancer
5 through the action of TNF-alpha are to be improved.

Consequently, another object of the invention is consisting in a therapeutical method of treating, by stimulation of the production of TNF-alpha, of tumors and more generally of cancers of the group comprising breast cancer, lung cancer, oesophagus cancer, stomach cancer, intestine and colon
10 cancers, and of viral, bacterial and fungal diseases as well as diseases related to immunostimulant deficiencies of human beings and warm-blood animals, said method comprising administration to a patient of an effective amount of preferably soluble laminarin.

The above said preferably soluble laminarin is comprised within a composition said laminarin and a pharmaceutically acceptable carrier, the
15 amount of laminarin being effective to treat the tumor, the cancer or the disease.

In connection with the experiments carried out in that respect by Applicants, Balb/c mice were intraperitoneally injected with 250mg of
20 laminarin or lentinan (purchased from Sigma St. Louis, MO, USA) in PBS.

Mice of a control group were treated with PBS only.

After various time intervals (10, 30, 60 and 90 minutes, respectively), after the injection of laminarin, Lentinan and PBS only, the mice were killed and blood was collected in Eppendorf tubes.

25 Subsequently, the serum of the collected blood was separated, collected and stored at -80°C for no more than 1 week.

The level of TNF-alpha in the serum samples was evaluated using a commercial kit marketed as OptEIA Mouse TNF-alpha (Mono/Mono) Set by the Company Pharmingen, San Diego, CA, USA) ; the manufacturer's
30 instructions were followed.

In that respect, wells of 96-well plates were coated with 0.1 ml/well of capture antibody (provided in the above kit) diluted in coating buffer (also provided in the above kit); the expression "capture antibody" designates first antibody used for coating of wells ; this antibody captures the tested cytokines from the solution ; in this assay it was anti-mouse-TNF-alpha monoclonal antibody.

The plates were sealed and incubated overnight at 4°C.

Individual wells were emptied by aspiration and washed 3 times with over 300µl/well of wash buffer (also provided in the kit).

10 Reaction was blocked with 200µl/well of assay diluent (also provided in the kit) and by incubation for 60 minutes at room temperature.

Again, individual wells were emptied by aspiration and washed 3 times with over 300 µl/well of the same wash buffer.

Standards (also provided in the kit) and samples of serum were diluted in assay diluent (also provided in the kit) and pipetted (100µl/well) in appropriate wells ; as far as the dissolution rate is concerned standards (part of the kit) were diluted according to the instructions into following concentrations: 1000 pg/ml, 500 pg/ml, 250, 125, 62.5, 31.3, and 15.6 pg/ml.

20 The plates were sealed with plastic foils and incubated for 60 minutes at room temperature. Individual wells were emptied by aspiration and washed 3 times with over 300µl/well of same wash buffer.

A quantity of 100µl/well of substrate solution (also provided in the kit) was added to each well and the plates were incubated for 30minutes in the dark at room temperature; "substrate solution" is formed by mixing a substrate reagent A containing hydrogen peroxide and Substrate reagent B containing 3,3',5,5'- tetramethylbenzidine in organic solvent ; when mixed together, the reagent reacts with peroxidase-labeled conjugates to develop a blue color.

25 A quantity of 50µl/well of stop solution provided in the kit and adapted to stop the reaction was added to each well and the optical density was

determined using a STL ELISA reader (marketed by Tecan U.S., Research Triangle Park, NC) at 450nm with a correction at 570nm.

The concentration of TNF-alpha, in pg/ml, in the blood of the mice treated as hereabove disclosed has been determined at the following
5 moments : 10, 30, 60 and 90 minutes after the injection of soluble laminarin, Lentinan and control.

The values obtained are collected in Table II.

TABLE II

Concentration, in $\mu\text{g/ml}$ of TNF-alpha in mice treated with 250 μg of Soluble laminarin, Lentinan or Control (values recorded and standard deviation)				
Duration (in minutes) between injection and measurement	10	30	60	90
soluble laminarin	0	51.98+6.3	64.20+8.9	83.48+4.1
Lentinan	0	31.03+5.1	27.55+3.7	25.99+6.2
Control	0	1	0	2

10 Figure 2 is a graph representing the variation of the concentration expressed in $\mu\text{g/ml}$ of TNF-alpha in the blood of the experimental mice as a function of the duration t expressed in minutes of the action of either soluble laminarin, Lentinan or Control, these data being those of Table II.

In figure 2 the variations of TNF-alpha in the presence of soluble
15 laminarin, Lentinan and Control are illustrated by respectively curves A, B and C.

The conclusions which can be drawn from the data collected in table II and from figure 2 are that the indirect activation of macrophages and cytotoxic T lymphocytes, measured as the increase of TNF-alpha secretion is
20 significantly higher when using especially soluble laminarin instead of Lentinan.

From the two above described sets of experiments it appears that soluble laminarin has a double effect on immune reactions both specific via

activation of NK cells and non specific via stimulation of TNF alpha production.

Consequently, Applicants have demonstrated that soluble laminarin therapy constitutes a promising treatment of various diseases including cancer
5 and other diseases which comprise infection diseases such as bacterial ,viral, fungal or opportunistic diseases , immune diseases , auto-immune diseases , allergic diseases, and all diseases in which the immune system in mammals needs to be stimulated.

The contemplated therapies involve the posologies and the
10 pharmaceutical forms hereafter disclosed.

Dosages vary in a wide range depending essentially on the mode of administration.

In that respect when administrated intravenously the dosis of soluble laminarin is from about 0,1 to 10mg per day.

15 In the case of the intraperitoneally mode the dosis is from about 0,1 to about 50mg/kg per day during a period of from 5 to 15 days ; that period can possibly be reiterated.

By oral administration, the dosis varies from about 1 to about 100 and is preferably of about 10mg/kg, advantageously twice a week over extended
20 periods of time and possibly for the whole life of the patient.

In that respect, an object according to the invention is consisting in a therapeutical method of treating tumors and more generally cancers of the group comprising breast cancer, lung cancer, oesophagus cancer, stomach cancer, intestine and colon cancers, and viral, bacterial and fungal diseases as
25 well as diseases related to immunostimulant deficiencies of human beings and warm-blood animals, by intravenous administration of an amount of from 0,1 to 10mg per day of preferably soluble laminarin.

Another object according to the invention is consisting in a therapeutical method of treating tumors and more generally of cancers of the group
30 comprising breast cancer, lung cancer, oesophagus cancer, stomach cancer,

intestine and colon cancers, and of viral, bacterial and fungal diseases as well as diseases related to immunostimulant deficiencies of human beings and warm-blood animals, by intraperitoneally administration of from 0,1 to about 50mg/kg per day during a period of from 5 to 15 days of preferably soluble
5 laminarin.

Another object according to the invention is consisting in a therapeutical method of treating tumors and more generally of cancers of the group comprising breast cancer, lung cancer, oesophagus cancer, stomach cancer, intestine and colon cancers, and of viral, bacterial and fungal diseases as well
10 as diseases related to immunostimulant deficiencies of human beings and warm-blood animals, by oral administration, of from 1 to 100 and, preferably, of about 10mg/kg, advantageously twice a week over extended periods of time, of preferably soluble laminarin.

Laminarin, especially in its soluble form is considered as safe.

15 Its LD 50 is high and was determined as to be greater than 2000mg/Kg given orally in rats; furthermore there are no special handling requirements.

The medicinal formulations according to the invention comprise an effective amount of soluble laminarin, and advantageously, a potentiator
20 generally mixed with a pharmaceutically acceptable carrier.

By the term "potentiator" is designated a material that improves or increases the efficiency of laminarin or acts on the immune system as immuno-modulator and is used in combination with laminarin.

The "pharmaceutical acceptable carrier" is selected from the group
25 comprising pharmaceutically acceptable solvents, suspending agents or vehicles, and in function of the route selected for administration, and keeping in mind standard pharmaceutical practice ; "acceptable" means that the carrier is compatible with the other ingredients of the formulation and not injurious to the patient.

More generally, a "pharmaceutically acceptable component" should not present or induce undue adverse side effects such as toxicity, irritation, and allergic response and should be commensurate with a reasonable benefit/risk ratio.

5 Oral formulations suitable for use in connection with the present invention include capsules, gels, cachets, effervescent or non-effervescent powders, tablets, and granules ; they may consist of a solution, of a suspension in an aqueous or non-aqueous liquid, of an oil-in-water liquid emulsion or of a water-in-oil emulsion.

10 The pharmaceutical forms through which laminarin is administered may also be presented as a bolus, an electuary, or a paste.

Generally, the said formulations may be prepared by uniformly mixing the active ingredient, i.e. especially soluble laminarin with liquid carriers or finely divided solid carriers or both, and then if necessary by shaping the
15 product.

Suitable solid carriers comprise lactose, sucrose, gelatin, agar and bulk powders.

Suitable liquid carriers comprise water, pharmaceutically acceptable fats and oils, alcohol or other organic solvents, including esters, emulsions, syrups or elixirs, suspensions, solutions and/or suspensions, and solutions and
20 or suspensions reconstituted from non-effervescent granules and effervescent preparations reconstituted from effervescent granules.

They also may comprise preservatives, emulsifying agents, suspending agents, diluents, sweeteners, thickeners, and melting agents ; preferred liquid
25 carriers are edible oils, for example, corn or canola oils, as well as polyethylene glycols or PEG.

The therapeutical forms, intended for oral administration, comprise non-toxic, pharmaceutically acceptable, inert carriers selected from the group comprising lactose, starch, sucrose, glucose, methyl cellulose, magnesium

stearate, dicalcium phosphate, calcium sulfate, mannitol, sorbitol, cyclodextrin, and cyclodextrin derivatives.

Capsules or tablets containing laminarin according to the invention should preferably be easy to swallow or to chew, and contain carriers,
5 binders, lubricants, diluents, disintegrating agents, coloring agents, flavoring agents, flow-inducing agents, or melting agents ; they may be produced by compression or molding, optionally with one or more classical additional ingredients.

The tablets are optionally coated and may be formulated so as to
10 provide slow-or controlled-release of the active ingredient. Tablets may also optionally be provided with an enteric coating to provide release in parts of the gut other than the stomach.

Laminarin may additionally be combined with chemotherapeutic agents, or potentiators, to provide a combination therapy.

15 Combination therapy can be sequential, that which means the treatment is carried out with one agent first and then with the second agent ; or it can be a treatment with both agents at the same time. The sequential therapy can be performed within a reasonable time after the completion of the first therapy before beginning the second one. The treatment with both agents at the same
20 time can be in the same daily dose or separate doses.

For example :

- in the case of retroviral infection, a combination therapy may consist in treatment with soluble laminarin together with nucleosides analogues, (with inhibitors of reverse transcriptase), such as AZT or with proteases
25 inhibitors such as Ritonavir.
- in the case of cancer diseases a combination therapy may consist in treatment with soluble laminarin together with topo-isomerase inhibitors, such as Topotecan, Anthracycline, or antimetabolites such as Cytarabine, Fluorouracil and others.

Example a

Laminarin containing Tablet

A large number of tablets are prepared by conventionnal procedures so that the dosage unit was 100 mg of active ingredient per tablet :

- | | | |
|----|--|---------|
| 5 | - soluble laminarin in lyophilised form..... | 100 mg |
| | - colloïdal silicon dioxide..... | 0,2 mg |
| | - Magnesium stearate..... | 5 mg |
| | - Microcristalline cellulose..... | 270 mg |
| | - Starch..... | 10 mg |
| 10 | - Mannitol..... | 98,8 mg |

Appropriate coating can be applied to increase palatability and or delay absorption.

Example b

- 15 Laminarin containing granules.

An amount of 1 liter of an aqueous solution containing 75 g of soluble laminarin is mixed with 10g of dextrin, the thus obtained mixture being absorbed into a food base i.e starch, sorbitol, carboxy-methyl-cellulose, lactose, mannitol, guar gum, vanilline.

- 20 The resulting powder is extruded to form an extrusion granulate using a net of 1 mm. The granules are sieved on a 12 mesh sieve and the resulting granules are dried at 60° C overnight in a drier to provide granules containing about 25 % by weight of laminarin and about 3 % of moisture.

These granules are used as an additive to drinking water or the like.

- 25 For example, for these granules, a posology of 6 to 9 tea spoons per day for and adult and 2 or 3 tea spoons per day for a children is recommended.

Example c

Insoluble laminarin containing pharmaceutical forms for oral administration :

1- lozenges consisting of

- | | | |
|----|-------------------------------------|----------------------|
| 30 | - insoluble laminarin powder..... | 5 parties by weight |
| | - mannitol as flavored carrier..... | 20 parties by weight |

- starch 25 parties by weight
- sorbitol..... 30 parties by weight
- Sucrose..... 20 parties by weight

5 2- Mouthwashes

- laminarin.....1 %
- liquid carrier consisting of xylitol cristal, sodium cyclamate, alcool, sorbic acid, mint aroma, menthol, eugenol, sodium parahydroxybenzoate and purified water.

10 Example d

Soluble laminarin containing pharmaceutical form for vaginal administration ; vaginal cream with 1 % of soluble laminarin :

- Soluble laminarin.....1 %
- Excipient : vaseline, non-ionic emulsionable wax, liquid paraffine, glycine, sodium hydroxyde concentrated solution qsp pH = 4 to 5, sorbic acid, purified water.

Example e

Soluble laminarin containing pharmaceutical form for rectal administration presented as a suppository with a formulation expressed per suppository :

- 20 - Soluble powder laminarin 8 mg
- Retinol concentrate or synthetic
vitamine A in oily form.....1500 UI
- Excipients : semi-synthetic glycerides

25

Exemple f

Soluble laminarin containing pharmaceutical form for nasal administration which may be administrated in a liquid form, as a nasal spray.

- 30 - soluble laminarin..... 1 %
- benzoic acid.....200 mg

- Excipients : potassium sulfate, potassium hydroxyde, benzalkonium chloride, alcool, rosemary essential oil, purified water qsp.

Example g

5 Soluble laminarin containing pharmaceutical form for parenteral administration as an injectable solution for an ampoule of 1 ml

- Soluble laminarin2 mg
- Excipients : chlorhydric acid or sodium hydroxyde qsp pH : 5,0 to 7,5, USP water for injection

10

Example h

- Soluble laminarin containing veterinary formulation for example an udder gel with 5 % of soluble laminarin :
- Soluble laminarin5 %
- 15 - Salicylic acid1 %
- Excipients : propylene glycol, hypromellose, potassium sorbate, purified water

CLAIMS

1. Therapeutical method comprising administration to a patient of an effective amount of especially soluble laminarin for the treatment of tumors and more generally of cancers of the group comprising breast cancer, lung cancer, oesophagus cancer, stomach cancer, intestine and colon cancers, and for the treatment of viral, bacterial and fungal diseases as well as diseases related to immunostimulant deficiencies of human beings and warm-blood animals.
2. Therapeutical method of treating, by stimulation of the NK cells of a patient, of tumors and more generally of cancers of the group comprising breast cancer, lung cancer, oesophagus cancer, stomach cancer, intestine and colon cancers , and of viral, bacterial and fungal diseases as well as diseases related to immunostimulant deficiencies of human beings and warm-blood animals, comprising administration to a patient of an effective amount of especially soluble laminarin.
3. Therapeutical method of treating, by stimulation of the production of TNF-alpha, of tumors and more generally of cancers of the group comprising breast cancer, lung cancer, oesophagus cancer, stomach cancer, intestine and colon cancers, and of viral, bacterial and fungal diseases as well as diseases related to immunostimulant deficiencies of human beings and warm-blood animals, comprising administration to a patient of an effective amount of especially soluble laminarin.

4. Therapeutical method of treating tumors and more generally of cancers of the group comprising breast cancer, lung cancer, oesophagus cancer, stomach cancer, intestine and colon cancers, and of viral, bacterial and fungal diseases as well as diseases related to immunostimulant deficiencies of human beings and warm-blood animals, by intravenous administration of an amount of from 0,1 to 10mg per day of preferably soluble laminarin.
5. Therapeutical method of treating tumors and more generally of cancers of the group comprising breast cancer, lung cancer, oesophagus cancer, stomach cancer, intestine and colon cancers, and of viral, bacterial and fungal diseases as well as diseases related to immunostimulant deficiencies of human beings and warm-blood animals, by intraperitoneally administration of from 0,1 to about 50mg/kg per day during a period of from 5 to 15 days of preferably soluble laminarin.
6. Therapeutical method of treating tumors and more generally of cancers of the group comprising breast cancer, lung cancer, oesophagus cancer, stomach cancer, intestine and colon cancers, and of viral, bacterial and fungal diseases as well as diseases related to immunostimulant deficiencies of human beings and warm-blood animals, by oral administration, of from 1 to 100 and, preferably, of about 10mg/kg, advantageously twice a week over extended periods of time, of preferably soluble laminarin.
7. A therapeutical method comprising administration of an amount of laminarin, preferably soluble laminarin, comprised within a composition comprising said laminarin and a pharmaceutically

acceptable carrier, to a human or to a warm-blood animal suffering from a tumor or from a cancer or from a viral disease, a bacterial disease, a fungal disease, a disease of the immune system, an auto-immune disease or a disease related to a deficiency of immunostimulation in the human or animal, wherein the amount of laminarin is effective to treat the tumor or cancer or the disease.

8. Combinaison therapy consisting in therapeutical treatment of tumors and more generally of cancers of the group comprising breast cancer, lung cancer, oesophagus cancer, stomach cancer, intestine and colon cancers, and of viral, bacterial and fungal diseases as well as diseases related to immunostimulant deficiencies of human beings and warm-blood animals, by administration of effective amounts of respectively laminarin and chemo-therapeutic agents or potentiators.




FIG.1.




FIG.2.